Spyre Therapeutics, Inc.SYRENASDAQ
Loading
Year-over-year revenue growth rate
Latest
0.00%
↓ 100% vs avg
Percentile
P28
Within normal range
Average
1.04%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | 0.00% |
| Q3 2025 | 0.00% |
| Q2 2025 | 0.00% |
| Q1 2025 | 0.00% |
| Q4 2024 | 0.00% |
| Q3 2024 | 0.00% |
| Q2 2024 | 0.00% |
| Q1 2024 | 0.00% |
| Q4 2023 | 0.00% |
| Q3 2023 | -100.00% |
| Q2 2023 | 247.47% |
| Q1 2023 | 17.86% |
| Q4 2022 | -3.45% |
| Q3 2022 | -72.16% |
| Q2 2022 | -54.11% |
| Q1 2022 | -62.62% |
| Q4 2021 | 160.47% |
| Q3 2021 | -89.79% |
| Q2 2021 | 0.00% |
| Q1 2021 | 0.00% |
| Q4 2020 | 0.00% |
| Q3 2020 | 0.00% |
| Q2 2020 | 0.00% |
| Q1 2020 | 0.00% |
| Q4 2019 | 0.00% |
| Q3 2019 | 0.00% |
| Q2 2019 | 0.00% |
| Q1 2019 | 0.00% |
| Q4 2018 | 0.00% |
| Q3 2018 | -100.00% |
| Q2 2018 | 57.48% |
| Q1 2018 | 1.89% |
| Q4 2017 | 17.53% |
| Q3 2017 | -14.74% |
| Q2 2017 | 50.61% |
| Q1 2017 | -21.25% |
| Q4 2016 | 8.53% |
| Q3 2016 | -16.31% |
| Q2 2016 | 59.84% |
| Q1 2016 | -45.80% |